FDA recently approved Pfizer’s Xeljanz (tofacitinib) to treat adults with active ankylosing spondylitis (AS).
The agency approved the drug specifically for individuals who have had an inadequate...
Bristol Myers Squibb and clinical-stage biopharmaceutical company Immatics recently entered into a license, development, and commercialization agreement for the bispecific T-cell candidate,...
Kite, a Gilead Company, recently announced positive primary results from a Phase 2 study of Yescarta in patients with high-risk large B-cell lymphoma (LBCL).
The global ZUMA-12 study enrolled 42...
Johnson & Johnson recently announced longer-term results from the Phase 1b/2 study evaluating the safety and efficacy of its T-cell (CAR-T) therapy for patients with relapsed or refractory multiple...
Pfizer recently entered into a $6.7 billion proposed pharma acquisition deal with Arena Pharmaceuticals to develop therapies for chronic disease management.
Arena Pharmaceutical’s...
Roche recently launched the AVENIO Edge System to advance next-generation sequencing (NGS) technologies.
Researchers can use the pre-analytical program for sequencing library preparation, target...
AstraZeneca recently entered into a global development and commercialization agreement with Ionis Pharmaceuticals for transthyretin amyloidosis medication, eplontersen.
Eplontersen is a...
GSK recently welcomed the decision of the Gavi Board to fund the procurement and introduction of malaria vaccines into routine child immunization programs in eligible countries.
GSK developed its...
GSK and the University of Oxford recently entered into a five-year collaboration to improve the success and speed of research and development of new medicines and unravel mechanisms of disease.
GSK...
GSK recently launched an international, multi-year initiative to advance innovation and address key needs in the multiple myeloma community.
The project, Target the Future, will provide education on...
FDA recently approved imaging drug Cytalux to assist surgeons in identifying ovarian cancer lesions.
Cytalux is approved for use in adult patients with ovarian cancer to help identify...
Novo Nordisk recently entered into a pharma acquisition deal with Dicerna Pharmaceuticals to increase its pipeline of RNAi therapies and technology platforms.
Dicerna develops RNAi-based...
FDA recently approved Voxzogo injection for children five years of age and older with achondroplasia and open epiphyses.
Achondroplasia is the most common form of dwarfism. Individuals living...
Gilead recently added three programs in Arcus Biosciences’ clinical-stage portfolio, including antibodies and small molecules, to its oncology pipeline.
Specifically, Gilead exercised its...
Moderna recently announced that its mRNA therapeutic for heart failure patients undergoing coronary artery bypass grafting (CABG) surgery met its primary endpoint in a Phase 2 study.
The...
FDA recently granted breakthrough device designation for Datar Cancer Genetics’ blood test to detect early-stage breast cancer.
The test, TriNetra, uses proprietary technology to detect...
FDA recently approved PharmaEssentia’s injection to treat adults with polycythemia vera, a rare blood disease that causes overproduction of red blood cells.
The monopegylated, long-acting...
Abbott recently released research from its multi-year global research program, which found that advancing diagnostic testing for vascular diseases can help hospitals and physicians improve the patient...
Bristol Myers Squibb recently announced that Opdivo plus chemotherapy significantly improved event-free survival (EFS) in patients with resectable stage IB to IIIA non-small cell lung cancer...
Pfizer and Biohaven Pharmaceuticals recently collaborated to commercialize rimegepant, a generic drug used to treat migraine attacks, in markets outside of the US.
Commercialized as Nurtec ODT in the...
